Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Pharma & Biotech

Tempest Therapeutics, Inc. bets on dual-targeting CAR-T to address antigen escape challenges

Tempest Therapeutics, Inc. advances TPST-2003 CAR-T data. Discover how dual-targeting could impact multiple myeloma treatment durability.

Read More
Pharma & Biotech

Is Rein Therapeutics, Inc.’s Phase 2 execution enough to differentiate LTI-03 in IPF

Rein Therapeutics advances LTI-03 in Phase 2 IPF trial. Find out what this means for fibrosis drug competition and clinical development today.

Read More
Medical Devices & Diagnostics Pharma & Biotech

Merck KGaA just made a quiet digital-health move. Could hybrid drugs be pharma’s next big reset?

Digital therapeutics struggled alone. Remepy and Merck KGaA are testing whether software works better when built into the drug itself.

Read More
Pharma & Biotech

What Juniper Biosciences’ MSK collaboration means for radiation dose de-escalation strategies

Find out how Juniper Biosciences is using FMISO imaging to personalize radiation therapy and reduce toxicity in head and neck cancer.

Read More
Pharma & Biotech

What Biomolecular Holdings LLC’s platform patents reveal about the future of antibody engineering

Biomolecular Holdings LLC secures platform patents for tetrahedral antibodies. Discover what this means for the future of antibody engineering.

Read More
Pharma & Biotech

AbbVie Inc. secures strategic option on Kestrel Therapeutics Inc. amid KRAS innovation race

A new pan-KRAS approach enters Phase 1 backed by AbbVie Inc. Discover the implications for oncology pipelines and KRAS-driven cancers.

Read More
Pharma & Biotech

Could BioCardia, Inc.’s integrated platform overcome variability in cardiac regenerative treatments

Discover how BioCardia, Inc.’s Heart3D platform could reduce variability in cardiac cell therapy. Read the full analysis on what this means next.

Read More
Representative image of an oncology consultation involving lung scan review, reflecting how Xcovery Holdings’ Ensacove launch and EVERSANA’s commercialization support could influence patient access in ALK-positive non-small cell lung cancer care.
Pharma & Biotech

Can EVERSANA help Xcovery turn Ensacove into a serious ALK-positive lung cancer contender?

ALK lung cancer has strong therapies already. Xcovery’s Ensacove now faces the harder test of access, adoption, and differentiation.

Read More
Representative image of sterile injectable medicine vials being reviewed in a hospital pharmacy setting, reflecting how Apotex’s generic Infuvite Pediatric Injection approval could expand access to pediatric parenteral nutrition and complex generic injectables in the United States.
Pharma & Biotech

How Apotex’s generic Infuvite pediatric approval could shift the sterile injectable multivitamin market

Pediatric nutrition needs reliable sterile supply. Apotex’s Infuvite generic approval tests whether complex generics can ease that gap.

Read More
Representative image of a clinical consultation on long-term schizophrenia care, as Johnson & Johnson’s CAPLYTA FDA label update sharpens focus on relapse prevention, treatment stability, and durability in neuropsychiatric therapy.
Pharma & Biotech

Johnson & Johnson’s CAPLYTA update raises the bar for long-term schizophrenia stability

Schizophrenia drugs face a durability test. CAPLYTA’s FDA update gives Johnson & Johnson a stronger long-term stability story.

Read More